Navigation Links
Sigma-Aldrich Names Helge Bastian New VP of Global Marketing for Research Biotech

ST. LOUIS, Feb. 19 /PRNewswire-FirstCall/ -- Sigma-Aldrich(R) (Nasdaq: SIAL) is pleased to announce that Helge Bastian, Ph.D, has joined Sigma-Aldrich as Vice President of Global Marketing for the Research Biotech business unit. Dr. Bastian will be responsible for our strategic and commercial marketing efforts to drive top line growth through the identification, development and launch of innovative products into the life science market. Dr. Bastian has over 15 years of international leadership experience in the molecular biology and diagnostics, biotechnology, drug development and pharmaceutical manufacturing industry.

He was previously executive vice president of the Life Science Services business unit at SGS, a leading inspection, verification and certification company, and member of the senior executive management team in Geneva, Switzerland. Helge held various management positions at QIAGEN for more than 11 years, including Vice President of Molecular Diagnostics, Vice President of Global Strategic Marketing and Vice President of PreAnalytiX, and member of QIAGEN's executive steering committee and PreAnalytiXs management committee.

Helge studied biology at the Universities in Kiel, Gottingen, and Munich, Germany, and holds a diploma in biology (focus area of biochemistry) and a Ph.D. in molecular biology conducted at the Max-Planck Institute for Biophysical Chemistry from the University of Gottingen, Germany. He is an alumnus from the Max-Planck Network and the Columbia Business School.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers
2. Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
3. Sigma-Aldrich Corporations 4th Quarter 2007 Earnings Conference Call
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. Sigma-Aldrich Announces Launch of a New Antibodies Catalog
6. Saint Louis University Honors Sigma-Aldrich Corp. for $1 Million Donation
7. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
8. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
11. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):